Scientists developed a bifunctional therapeutic strategy by transforming living tumor cells into a therapeutic. Shah’s team engineered living tumor cells using the gene editing tool CRISPR-Cas9 and repurposed them to release tumor cell killing agent. In addition, the engineered tumor cells were designed to express factors that would make them easy for the immune system to spot, tag and remember, priming the immune system for a long-term anti-tumor response. The team tested their repurposed CRISPR-enhanced and reverse-engineered therapeutic tumor cells (ThTC) in different mice strains including the one that bore bone marrow, liver and thymus cells derived from humans, mimicking the human immune microenvironment. Shah’s team also built a two-layered safety switch into the cancer cell, which, when activated, eradicates ThTCs if needed. Credit: Kok Siong Chen and Khalid Shah.Become a supporter of this podcast: https://www.spreaker.com/podcast/world-reading-club-w-r-c--5667160/support.Stay awake and vibrant with Strong Coffee Company. An exclusive deal you'll not get elswhere. This is another way to support my work using the code HAKEEM.I earn commissions when you buy anything from Strong Coffee Company using my link and code "HAKEEM" https://MyDeals.Page/1gp9If you want to dig in deeper to more of my productions, go to World Reading Club.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related